| scholarly article | Q13442814 |
| P50 | author | Sabine Müller | Q89245124 |
| P2093 | author name string | Xi Huang | |
| C David James | |||
| Nalin Gupta | |||
| Zhiguo Zhang | |||
| Pamela L Paris | |||
| Xiaoyue Chen | |||
| Haiyun Gan | |||
| Rintaro Hashizume | |||
| Dong Fang | |||
| David Solomon | |||
| Claudia Petritsch | |||
| Todd A Waldman | |||
| Noemi Andor | |||
| Robin Lerner | |||
| Vy Ngo | |||
| Maxwell W Tom | |||
| Yuichiro Ihara | |||
| P2860 | cites work | Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas | Q24339074 |
| Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas | Q24629777 | ||
| A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response | Q27670940 | ||
| Fast gapped-read alignment with Bowtie 2 | Q27860699 | ||
| Role of histone H3 lysine 27 methylation in Polycomb-group silencing | Q28131795 | ||
| UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development | Q28241669 | ||
| EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations | Q29615392 | ||
| Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma | Q29616862 | ||
| ChIPpeakAnno: a Bioconductor package to annotate ChIP-seq and ChIP-chip data | Q33575507 | ||
| Polycomb complexes and silencing mechanisms. | Q34320981 | ||
| Brainstem glioma: a review | Q34628180 | ||
| The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression | Q36850449 | ||
| Evaluation of histone 3 lysine 27 trimethylation (H3K27me3) and enhancer of Zest 2 (EZH2) in pediatric glial and glioneuronal tumors shows decreased H3K27me3 in H3F3A K27M mutant glioblastomas | Q36981245 | ||
| Design and analysis of ChIP-seq experiments for DNA-binding proteins | Q37003887 | ||
| An experimental xenograft mouse model of diffuse pontine glioma designed for therapeutic testing | Q37344059 | ||
| Targeting Wee1 for the treatment of pediatric high-grade gliomas | Q37580495 | ||
| Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma | Q38259785 | ||
| Histone H3.3. mutations drive pediatric glioblastoma through upregulation of MYCN. | Q39173934 | ||
| Characterization of a diffuse intrinsic pontine glioma cell line: implications for future investigations and treatment | Q39277587 | ||
| Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. | Q55470277 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacology | Q128406 |
| Brainstem glioma | Q4955921 | ||
| P304 | page(s) | 1394-1396 | |
| P577 | publication date | 2014-11-17 | |
| P1433 | published in | Nature Medicine | Q1633234 |
| P1476 | title | Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma | |
| P478 | volume | 20 |
| Q100762137 | 2-Oxoglutarate-dependent dioxygenases in cancer |
| Q30378316 | A cellular chemical probe targeting the chromodomains of Polycomb repressive complex 1 |
| Q39147132 | A chemical probe toolbox for dissecting the cancer epigenome |
| Q28829593 | A histone H3K9M mutation traps histone methyltransferase Clr4 to prevent heterochromatin spreading |
| Q55365965 | A new metabolic gene signature in prostate cancer regulated by JMJD3 and EZH2. |
| Q64059831 | ALK2 inhibitors display beneficial effects in preclinical models of mutant diffuse intrinsic pontine glioma |
| Q33772355 | Actionable molecular biomarkers in primary brain tumors |
| Q38725573 | Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance. |
| Q38777058 | Advances in the molecular genetics of gliomas - implications for classification and therapy |
| Q28074465 | Alterations of Epigenetic Regulators in Pancreatic Cancer and Their Clinical Implications |
| Q89326663 | An MDS-derived cell line and a series of its sublines serve as an in vitro model for the leukemic evolution of MDS |
| Q38682159 | An epigenetic gateway to brain tumor cell identity |
| Q48424265 | An epigenetic therapy for diffuse intrinsic pontine gliomas. |
| Q42362644 | BMI-1 is a potential therapeutic target in diffuse intrinsic pontine glioma |
| Q26739232 | Brainstem Glioma in Adults |
| Q91694051 | CATACOMB: An endogenous inducible gene that antagonizes H3K27 methylation activity of Polycomb repressive complex 2 via an H3K27M-like mechanism |
| Q55351090 | CDK4/6 and PDGFRA Signaling as Therapeutic Targets in Diffuse Intrinsic Pontine Glioma. |
| Q48405952 | Cancer. For pediatric glioma, leave no histone unturned |
| Q53769248 | Characteristics of H3 K27M-mutant gliomas in adults. |
| Q37062230 | Chromatin Landscape of the IRF Genes and Role of the Epigenetic Reader BRD4. |
| Q64884332 | Chromatin remodeling defects in pediatric brain tumors. |
| Q92662658 | Combined Targeting of Mutant p53 and Jumonji Family Histone Demethylase Augments Therapeutic Efficacy of Radiation in H3K27M DIPG |
| Q58746764 | Combined use of CDK4/6 and mTOR inhibitors induce synergistic growth arrest of diffuse intrinsic pontine glioma cells via mutual downregulation of mTORC1 activity |
| Q61443106 | Comprehensive profiling of JMJD3 in gastric cancer and its influence on patient survival |
| Q38518851 | Context-dependent actions of Polycomb repressors in cancer |
| Q89989911 | Coordinated demethylation of H3K9 and H3K27 is required for rapid inflammatory responses of endothelial cells |
| Q47169542 | Current trends in mouse models of glioblastoma. |
| Q57811969 | Cutting Edge Therapeutic Insights Derived from Molecular Biology of Pediatric High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG) |
| Q88911074 | Cystathionine-γ-lyase ameliorates the histone demethylase JMJD3-mediated autoimmune response in rheumatoid arthritis |
| Q26777843 | DIPG in Children - What Can We Learn from the Past? |
| Q33568113 | Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma |
| Q67200898 | Developmental origins and emerging therapeutic opportunities for childhood cancer |
| Q91787755 | Differential kinase activity of ACVR1 G328V and R206H mutations with implications to possible TβRI cross-talk in diffuse intrinsic pontine glioma |
| Q55285428 | Diffuse Intrinsic Pontine Glioma : Clinical Features, Molecular Genetics, and Novel Targeted Therapeutics. |
| Q30251385 | Diffuse Intrinsic Pontine Glioma: New Pathophysiological Insights and Emerging Therapeutic Targets |
| Q38963434 | Diffuse Intrinsic Pontine Glioma: Time for Cautious Optimism |
| Q46961572 | Diffuse Midline Gliomas with Histone H3-K27M Mutation: A Series of 47 Cases Assessing the Spectrum of Morphologic Variation and Associated Genetic Alterations |
| Q47580461 | Diffuse intrinsic pontine gliomas-current management and new biologic insights. Is there a glimmer of hope? |
| Q61446934 | Emerging roles of telomeric chromatin alterations in cancer |
| Q33737472 | Epigenetic Regulation of Telomere Maintenance for Therapeutic Interventions in Gliomas. |
| Q39154575 | Epigenetic Targeted Therapy for Diffuse Intrinsic Pontine Glioma |
| Q58554073 | Epigenetic Targeting of Glioblastoma |
| Q38852455 | Epigenetic balance of gene expression by Polycomb and COMPASS families |
| Q39069889 | Epigenetic modification in chromatin machinery and its deregulation in pediatric brain tumors: Insight into epigenetic therapies |
| Q47900778 | Epigenetic regulation in medulloblastoma |
| Q89802537 | Epigenetic reprogramming and chromatin accessibility in pediatric diffuse intrinsic pontine gliomas: a neural developmental disease |
| Q38633640 | Expression of CD70 (CD27L) Is Associated With Epithelioid and Sarcomatous Features in IDH-Wild-Type Glioblastoma. |
| Q55456542 | Functional diversity and cooperativity between subclonal populations of pediatric glioblastoma and diffuse intrinsic pontine glioma cells. |
| Q28833173 | Functionally defined therapeutic targets in diffuse intrinsic pontine glioma |
| Q26801858 | Future Clinical Trials in DIPG: Bringing Epigenetics to the Clinic |
| Q58586368 | GSKJ4 Protects Mice Against Early Sepsis via Reducing Proinflammatory Factors and Up-Regulating MiR-146a |
| Q47930128 | GSKJ4, an H3K27me3 demethylase inhibitor, effectively suppresses the breast cancer stem cells |
| Q37723508 | Genomic Insights into Diffuse Intrinsic Pontine Glioma. |
| Q46820292 | Glioma. |
| Q92702976 | H19-Dependent Transcriptional Regulation of β3 and β4 Integrins Upon Estrogen and Hypoxia Favors Metastatic Potential in Prostate Cancer |
| Q38670000 | H3 K27M mutations are extremely rare in posterior fossa group A ependymoma |
| Q91638185 | H3.3 K27M depletion increases differentiation and extends latency of diffuse intrinsic pontine glioma growth in vivo |
| Q47436402 | H3.3K27M Cooperates with Trp53 Loss and PDGFRA Gain in Mouse Embryonic Neural Progenitor Cells to Induce Invasive High-Grade Gliomas. |
| Q55447974 | H3.3K27M mutant proteins reprogram epigenome by sequestering the PRC2 complex to poised enhancers. |
| Q64923274 | H3.3K27M-induced chromatin changes drive ectopic replication through misregulation of the JNK pathway in C. elegans. |
| Q38906678 | H3K27 Methylation: A Focal Point of Epigenetic Deregulation in Cancer |
| Q48136694 | HIF activation causes synthetic lethality between the VHL tumor suppressor and the EZH1 histone methyltransferase. |
| Q94076885 | Highlights from the Literature |
| Q94379074 | Highlights from the Literature |
| Q47751767 | Histone H3 K27M mutations in adult cerebellar high-grade gliomas. |
| Q26865965 | Histone H3 mutations--a special role for H3.3 in tumorigenesis? |
| Q39437966 | Histone H3K27 Trimethylation Modulates 5-Fluorouracil Resistance by Inhibiting PU.1 Binding to the DPYD Promoter |
| Q90273603 | Histone demethylase UTX is a therapeutic target for diabetic kidney disease |
| Q36936241 | Histone demethylases in physiology and cancer: a tale of two enzymes, JMJD3 and UTX. |
| Q93166794 | Identification of the 2-Benzoxazol-2-yl-phenol Scaffold as New Hit for JMJD3 Inhibition |
| Q41629326 | Imaging Characteristics of Pediatric Diffuse Midline Gliomas with Histone H3 K27M Mutation. |
| Q97423438 | Impact of histological diagnosis on the treatment of atypical brainstem lesions |
| Q37618835 | Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs. |
| Q64389714 | Inhibition of the Histone H3K27 Demethylase UTX Enhances Tumor Cell Radiosensitivity |
| Q41866064 | Inhibitor of H3K27 demethylase JMJD3/UTX GSK-J4 is a potential therapeutic option for castration resistant prostate cancer |
| Q38832510 | Investigational new drugs for brain cancer |
| Q28084146 | JMJD3 as an epigenetic regulator in development and disease |
| Q104795166 | KDM6B is an androgen regulated gene and plays oncogenic roles by demethylating H3K27me3 at cyclin D1 promoter in prostate cancer |
| Q42776487 | KDM6B modulates MAPK pathway mediating multiple myeloma cell growth and survival. |
| Q57025295 | KDM6B overexpression activates innate immune signaling and impairs hematopoiesis in mice |
| Q39761149 | Long survival in a child with a mutated K27M-H3.3 pilocytic astrocytoma |
| Q38747872 | Marked for death: targeting epigenetic changes in cancer |
| Q39965737 | Molecular Diagnostics of Gliomas Using Next Generation Sequencing of a Glioma-Tailored Gene Panel |
| Q90508484 | Molecular Pathogenesis and Emerging Treatment for Glioblastoma |
| Q39406356 | Molecular profiling of sarcomas: new vistas for precision medicine. |
| Q35920105 | Multiplexed barcoded CRISPR-Cas9 screening enabled by CombiGEM. |
| Q37592666 | Mutated Chromatin Regulatory Factors as Tumor Drivers in Cancer |
| Q36716785 | Mutations in chromatin machinery and pediatric high-grade glioma |
| Q99710807 | Nanoparticle enhanced combination therapy for stem-like progenitors defined by single-cell transcriptomics in chemotherapy-resistant osteosarcoma |
| Q92514387 | Negative regulation of miR-1275 by H3K27me3 is critical for glial induction of glioblastoma cells |
| Q39167472 | New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M. |
| Q55456584 | New Molecular Insights and Potential Therapies for Diffuse Intrinsic Pontine Glioma. |
| Q45945184 | New therapeutic approaches for brainstem tumors: a comparison of delivery routes using nanoliposomal irinotecan in an animal model. |
| Q58798742 | Next-Generation Drugs and Probes for Chromatin Biology: From Targeted Protein Degradation to Phase Separation |
| Q88660924 | Notch-effector CSL promotes squamous cell carcinoma by repressing histone demethylase KDM6B |
| Q39013655 | Oncogenic Mechanisms of Histone H3 Mutations |
| Q91779674 | Oncohistone Mutations in Diffuse Intrinsic Pontine Glioma |
| Q49912296 | Oncohistones: drivers of pediatric cancers |
| Q26781872 | Open access chemical probes for epigenetic targets |
| Q92254249 | PRC2 is high maintenance |
| Q33705644 | PTEN regulates glioblastoma oncogenesis through chromatin-associated complexes of DAXX and histone H3.3. |
| Q92862783 | Patient-Derived Orthotopic Xenograft Models of Pediatric Brain Tumors: In a Mature Phase or Still in Its Infancy? |
| Q47158930 | Patient-derived DIPG cells preserve stem-like characteristics and generate orthotopic tumors |
| Q38841339 | Patient-derived Tumor Models for Diffuse Intrinsic Pontine Gliomas |
| Q33777868 | Pediatric high-grade glioma: biologically and clinically in need of new thinking |
| Q48633110 | Pediatric thalamic glioma with H3F3A K27M mutation, which was detected before and after malignant transformation: a case report |
| Q90286776 | Pharmacologic inhibition of lysine specific demethylase-1 (LSD1) as a therapeutic and immune-sensitization strategy in pediatric high grade glioma (pHGG) |
| Q89543117 | Pineal region glioblastomas display features of diffuse midline and non-midline gliomas |
| Q92979168 | Polycomb-mediated repression of EphrinA5 promotes growth and invasion of glioblastoma |
| Q91801618 | Potent anti-tumor efficacy of palbociclib in treatment-naïve H3.3K27M-mutant diffuse intrinsic pontine glioma |
| Q41109977 | Potential New Therapies for Pediatric Diffuse Intrinsic Pontine Glioma |
| Q26799976 | Pre-Clinical Models of Diffuse Intrinsic Pontine Glioma |
| Q55030833 | Precision cancer therapy is impacted by oncogene-dependent epigenome remodeling. |
| Q55456558 | Prospective Feasibility and Safety Assessment of Surgical Biopsy for Patients with Newly Diagnosed Diffuse Intrinsic Pontine Glioma. |
| Q28829460 | Prostate cancer epigenetics and its clinical implications |
| Q41140252 | RNA sequencing reveals resistance of TLR4 ligand-activated microglial cells to inflammation mediated by the selective jumonji H3K27 demethylase inhibitor |
| Q92946094 | Radiosensitization by Histone H3 Demethylase Inhibition in Diffuse Intrinsic Pontine Glioma |
| Q50027408 | Recent Advances in Intradural Spinal Tumors. |
| Q36380213 | Repurposing the anti-epileptic drug sodium valproate as an adjuvant treatment for diffuse intrinsic pontine glioma |
| Q92000012 | Role of RNA modifications in cancer |
| Q92281434 | Role of Radiation Therapy in the Management of Diffuse Intrinsic Pontine Glioma: A Systematic Review |
| Q30276280 | Role of Serum Amyloid A, Granulocyte-Macrophage Colony-Stimulating Factor, and Bone Marrow Granulocyte-Monocyte Precursor Expansion in Segmented Filamentous Bacterium-Mediated Protection from Entamoeba histolytica |
| Q58775918 | Schwann cell Myc-interacting zinc-finger protein 1 without pox virus and zinc finger: epigenetic implications in a peripheral neuropathy |
| Q38639065 | Shared ACVR1 mutations in FOP and DIPG: Opportunities and challenges in extending biological and clinical implications across rare diseases |
| Q47235728 | Significance of H3K27M mutation with specific histomorphological features and associated molecular alterations in pediatric high-grade glial tumors. |
| Q42321107 | Small molecule epigenetic screen identifies novel EZH2 and HDAC inhibitors that target glioblastoma brain tumor-initiating cells. |
| Q33798642 | Small molecules targeting histone demethylase genes (KDMs) inhibit growth of temozolomide-resistant glioblastoma cells |
| Q27317083 | Spatial genomic heterogeneity in diffuse intrinsic pontine and midline high-grade glioma: implications for diagnostic biopsy and targeted therapeutics |
| Q35824823 | Successful strategies in the discovery of small-molecule epigenetic modulators with anticancer potential |
| Q99419066 | Targeted inhibition of KDM6 histone demethylases eradicates tumor-initiating cells via enhancer reprogramming in colorectal cancer |
| Q88698026 | Targeted inhibition of histone H3K27 demethylation is effective in high-risk neuroblastoma |
| Q34552042 | Targeting Epigenetic Pathways in the Treatment of Pediatric Diffuse (High Grade) Gliomas |
| Q59830619 | Targeting Metalloenzymes for Therapeutic Intervention |
| Q64094681 | Targeting P16INK4A in uterine serous carcinoma through inhibition of histone demethylation |
| Q60917015 | Targeting Telomerase and ATRX/DAXX Inducing Tumor Senescence and Apoptosis in the Malignant Glioma |
| Q89586516 | Targeting and Therapeutic Monitoring of H3K27M-Mutant Glioma |
| Q36398751 | Targeting epigenetic regulations in cancer |
| Q47845301 | Targeting glioma stem-like cell survival and chemo-resistance through inhibition of lysine-specific histone demethylase KDM2B. |
| Q93017613 | Targeting of Histone Demethylases KDM5A and KDM6B Inhibits the Proliferation of Temozolomide-Resistant Glioblastoma Cells |
| Q64053923 | Tenascin-C expression contributes to pediatric brainstem glioma tumor phenotype and represents a novel biomarker of disease |
| Q47873982 | Thalamic Glioblastoma: Clinical Presentation, Management Strategies, and Outcomes. |
| Q53153703 | The Emerging Role of Histone Demethylases in Renal Cell Carcinoma. |
| Q91737728 | The Prognostic Significance Of JMJD3 In Primary Sarcomatoid Carcinoma Of The Lung, A Rare Subtype Of Lung Cancer |
| Q38921975 | The Role of Molecular Diagnostics in the Management of Patients with Gliomas |
| Q96576372 | The integrated genomic and epigenomic landscape of brainstem glioma |
| Q42366633 | The pharmacological role of histone demethylase JMJD3 inhibitor GSK-J4 on glioma cells |
| Q39074023 | The role of histone modifications and telomere alterations in the pathogenesis of diffuse gliomas in adults and children. |
| Q91595196 | The roles of DNA, RNA and histone methylation in ageing and cancer |
| Q50449052 | The transcription factor Olig2 is important for the biology of diffuse intrinsic pontine gliomas |
| Q38742530 | Therapeutic Hypothesis Testing With Rodent Brain Tumor Models. |
| Q39236500 | Therapeutic Targeting of Histone Modifications in Adult and Pediatric High-Grade Glioma |
| Q101051095 | Therapeutic effect of a histone demethylase inhibitor in Parkinson's disease |
| Q51415557 | Therapeutic potential of GSK-J4, a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemia. |
| Q38713523 | Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas. |
| Q92059786 | Therapeutically targeting head and neck squamous cell carcinoma through synergistic inhibition of LSD1 and JMJD3 by TCP and GSK-J1 |
| Q55069145 | Therapeutics: Winning combination. |
| Q46985603 | Transcriptional Dependencies in Diffuse Intrinsic Pontine Glioma |
| Q61816131 | USP7 Cooperates with NOTCH1 to Drive the Oncogenic Transcriptional Program in T-Cell Leukemia |
| Q52596997 | Virtual fragment screening identification of a novel Quinoline-5,8-dicarboxylic acid derivative as selective JMJD3 inhibitor. |
Search more.